The Use of an IL-1 Receptor Antagonist Peptide to Control Inflammation in the Treatment of Corneal Limbal Epithelial Stem Cell Deficiency

Figure 1

(a) Crude products from the synthesis of the IL-1ra analogue peptide (2606 Da) were analysed by mass spectrometry. Component intensity is shown on the -axis in arbitrary units. Prominent peaks are at m/z 1303 (2⁺) and 869 (3⁺) and correspond to the original peptide molecular weight. (b) HPLC chromatogram of crude products from the synthesis of IL-1ra analogue peptide (MW 2606 Da) indicated a single prominent peak at 15-minute retention time.

(a)

(b)